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ABSTRACT 
Objective: To formulate and characterize midazolam loaded niosomal transdermal patches for overcoming the frequent dosing and lower 
bioavailability complications associated with conventional therapy.  
Methods: The loaded niosomal transdermal patches were prepared by thin film hydration method. The preliminary evaluation and characterization 
studies was conducted to find the optimised formulation. The in vitro release and ex-vivo permeation studies were investigated. The 
histopathological studies and stability studies were also assessed. 
Results: The midazolam loaded niosomal transdermal patches of vesicle size and zeta potential 116.1±84.46 d. nm and 8.56±1.2 mV respectively 
was formulated. The characterizations of both niosome and niosomal transdermal patches were found to be within the acceptable limits. The in 
vitro drug release showed an initial burst release followed by sustained release for both optimised niosomal formulation N5 and optimised 
niosomal transdermal patch formulation NT5with a maximum activity at 97.3±0.35% and 98.9±0.20% respectively. The ex vivo permeation studies 
of niosomal transdermal patch NT5 was performed which showed a higher permeability than control solution with a flux value of 0.151. The 
histopathological studies of the optimised formulation showed no detectable lesions upon skin surface and irritations. The stability studies showed 
that patches were stable over 90 d in different atmospheric conditions.  
Conclusion: The midazolam loaded niosomal transdermal patch was found to be a promising nano drug delivery alternative which showed better 
entrapment, release with permeation profile for the daily management of epilepsy with decreased dosing frequency.  
Keywords: Status epilepticus, Midazolam, Niosome, Soya bean oil, Niosomal transdermal patch, Gelatin 




Epilepsy is a disorder of the brain characterised by an enduring 
predisposition to generate epileptic seizures and by neurobiologic, 
cognitive, psychological and social consequences of this condition 
[1]. The epilepsy associated seizures are distinct to a person and 
undetectable sometimes and thus require special attention. Seizure 
is an event of transient occurrence of signs or symptoms due to 
abnormal, excessive or synchronous neuronal activity of the brain 
which can vary from short to long periods of vigorous shaking [2]. 
The excited electrical activity underlying epilepsy is due to 
biochemical processes at the cellular level promoting neuronal 
hyperexcitability. Any abnormalities in the normal neuronal 
transmissions, starting from a single enzyme-receptor abnormality 
to several key cortical and subcortical structures are involved in 
generating clinical seizures [3]. Seizures arise from an excessively 
synchronous excitation and sustained discharge of a group of 
cortical neurons. Prevailing seizures tend to recrudesce and have no 
immediate underlying genesis which are the result of excessive and 
abnormal nerve cell activity in the cortex of the brain [4-6]. Many 
currently used medications, even intravenous preparations are 
found to be least effective in early stages of epilepsy treatment [7]. 
The currently used major formulations for treatment of epilepsy 
include oral dosages which were once promising approaches for 
treatment methods but were less efficient in its therapeutic effect 
[8]. Novel drug delivery research provide a wider opportunity for 
these limitations [9-11]. Niosomes are nanometre size hydrated 
vesicles composed of non-ionic lamellar lipid bilayer posing an 
amphiphilic infrastructure [12-15]. The drug gets encapsulated 
within the amphiphilic system of the biodegradable and biologically 
compatible carrier system [16]. The novel carrier molecules are 
formulated by admixture of non-ionic surfactants like Span 60 or 
from dialkylpolyglycerol ether class which is stabilised by 
incorporating waxy steroids like cholesterol [17-20]. The niosomes 
are already leading in the market where they are used to incorporate 
various anti-cancer, anti-inflammatory drugs as well as hormonal 
preparations [21]. Niosomes possess advantages than conventional 
liposomes and tackles the susceptibility of phospholipids to undergo 
oxidative degeneration and variations in quality of lipids [22]. The 
transdermal route of drug administration ensures systemic delivery of 
drug by applying a drug formulation onto intact and healthy skin thus 
ensuring sustained drug release and bypass of first-pass metabolism 
[23-26]. Transdermal drugs significantly delivers molecules in a 
potent quantity that overcome the conventional problems of oral 
dosing. Thusthe aim of the study was to develop midazolam loaded 
niosomal transdermal patchas an effective substitute for the existing 
maintenance therapiesused for controlling epileptic seizures [27].  
MATERIALS AND METHODS 
Materials and excipients 
The drug of choice, midazolam, was provided as a gift sample by 
Lake Chemicals Private Limited, Bangalore. Soya bean oil was 
obtained, fromSigma Aldrich. All other chemicals used in the 
experiment were of analytical grade. 
Preformulation studies 
Fourier transform infrared (FTIR) spectroscopy  
The FTIR spectra of drug and excipients were obtained to ascertain 
the compatibility between midazolam and selected polymers using 
FTIR spectrophotometer by KBr pellet method [28]. 
Solubility studies 
Solubility studies of drug were determined in different solvents such 
as distilled water, ethanol, methanol, isopropyl alcohol, acetone, n-
butyl alcohol and phosphate buffer pH (5.5). 
Melting point of the drug 
The melting point of the sample was determined by open capillary 
method [29]. 
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Partition coefficient  
Partition coefficient of midazolam in n-octanol was found out and 
the concentration of drug content in the aqueous layer is determined 
spectrophotometrically [30]. 
Lamda max of midazolam in methanol and phosphate buffer 
solution (PBS) 
The absorption maxima of midazolam in both 10 ml of methanol and 
PBS pH5.5 was found to be 220 nm using UV-Vis spectrophotometer 
[31]. 
Drug compatibility with excipients 
The compatibility of the drug with excipients is determined using 
FTIR spectral analysis [32]. 
X-Ray diffraction studies 
XRD pattern was documented for midazolam API, optimised 
niosome N5 and optimised niosomal patch NT5 on Joel JDX 8030 X-
ray diffractometer (MTI Corporation, USA) for a specified quantity of 
each preparation [33, 34]. 
Formulation of midazolam niosomeand transdermal patch 
preparation 
The niosomal dispersion of midazolam was prepared by thin film 
hydration method using rotary vacuum evaporator. Surfactant 
(span60), soya bean oil, cholesterol in ratio 2:1:0.75 was weighed 
and dissolved together in the round bottom flask containing 
methanol-chloroform mixture of ratio 2:1 together with glass beads. 
The round bottom flask is connected to a rotary vacuum evaporator 
and then vacuum was applied. This round bottom flask was rotated 
at 150rpm and bath temperature was set at 28 °C. In this first phase, 
the vacuum was applied to completely remove the solvents until the 
complete dried solid thin film was developed in the wall of the flask. 
The film was hydrated by adding PBS solution pH5.5 containing the 
dissolved drug. The hydrated solution was again agitated for 1hr at 
60 °C for complete hydration. The obtained niosome dispersion was 
sonicated using probe sonicator for 20 min to decrease the particle 
size. The obtained mixture was stirred for 1hr in a magnetic stirrer 
to obtain a uniform niosome [35-37]. 
The obtained niosomes were stored under normal room 
temperature and transdermal patches were prepared using solvent 
casting method. The polymer solution of gelatin was prepared in a 
250 ml beaker by adding 20 ml of distilled water at 35 °C. The 
1%PEG 4000 and 0.1% turpentine oil was added as permeation 
enhancers. To this the prepared niosomal dispersion was introduced 
and mixed well to get a homogenous mixture. The solution was 
poured to a petridish initially coated with glycerine to avoid sticking 
of the formulation. It was placed in hot air oven at a temperature of 
35 °C for 24 h to get a uniform transdermal patch [38]. 
Characterization 
Characterization of niosomes 
Vesicle size 
The size of niosomes was measured by optical microscopic method 
(Olympus Opto System, India) and optimised. The measurements 
were accomplished in triplicate for all samples of niosome [39].  
Zeta potential  
The zeta potential is also analysed by optical microscopic method 
(Olympus Opto System, India) and optimised. The measurements 
was accomplished in triplicate for all samples of niosome [40]. 
Entrapment efficiency 
The entrapment efficiency of midazolam in niosomes was 
determined by centrifugation method, were purified niosomal 
suspension was transferred to a centrifuge tube and placed in the 
cavities of ultra-centrifugation [41]. The drug entrapped was 
analysed in both separated layers and entrapment efficiency was 
calculated by analysing at 220 nm [42]. 
Scanning electron microscopy 
The scanning electron microscope (SEM) was used to scan the atomic 
surface of midazolam niosomes and niosomal transdermal patches 
which was view under electron microscope for shape and size [43, 44]. 
In vitro release studies 
The in vitro release studies of different niosomal formulations of 
midazolam was done by static dissolution method. The apparatus 
wasset up by introducing an open end tube aligned vertically to a 
beaker containing the 50 ml of PBS pH5.5 which acts as receptor 
compartment. The open end tube was tied with a cellophane 
membrane on one side which resembles the membrane acting as a 
barrier within the body, so that only the tip touches the surface of 
buffer solution. The reaction conditions were standardised throughout 
the study. The receptor compartment was filled with PBS pH5.5 and 
the donor compartment with 1 ml vesicular dispersion of niosomal 
midazolam. The beaker was placed on a magnetic stirrer for a definite 
study time and samples were withdrawn at regular intervals. For each 
withdrawal the fresh buffer was replaced into the beaker and collected 
samples were diluted using pH5.5. The percentage of drug release in 
the receptor medium was spectrophotometrically analysed using UV-
visible spectrophotometer at 220 nm [45]. 
Kinetic model of in vitro drug release studies 
The in vitro release studies data were fitted to various kinetic 
models like Zero order, First order, Higuchi Plot and Koresmeyer 
peppas plot to identify the model of drug release [46, 47]. 
Ex-vivo permeation study 
The permeation studies was done in Franz diffusion cell where the 
mucosal tissue was kept at the donor compartment and 1 ml of the 
formulation in the receptor compartment. With a needle, required 
aliquots at regular intervals were transferred to sample bottles and 
was replaced with 1 ml fresh buffer. The samples were suitably diluted 
and spectrophotometrically analysed by UV-VIS spectrophotometer at 
220 nm. The procedure was done for continuous 8 h and the optimised 
niosome formulation, optimised niosomal patch and drug in buffer 
PBS pH5.5 was used for the study [48-50]. 
Characterisation of niosomal transdermal patch 
Flatness 
The flatness test was cond1ucted circular patches prepared which 
were cut into three different longitudinal strips and measured for 
uniformity in flatness [51]. 
Swelling ratio  
The swelling properties of transdermal patches were found by 
placing completely dried patches in a beaker containing 250 ml of 
PBS pH5.5 and maintained it at 27 °C. After 24 h the patches were 
taken and measured the water uptake using a digital balance [52]. 
Weight uniformity 
The uniformity in weight of different transdermal patch 
formulations was done by separately weighing the selected patches 
individually calculated for its average.  
Thickness 
The thickness of transdermal patches was measured using screw 
gauge at different sites of the various formulations and average 
measurement of triplicate readings was taken [53].  
Percentage drug content 
1 cm2sized patches were cut out and dissolved in vortex shaker 
containing 5 ml of methanol for 5 min. The solution was made up to 
the volume by 10 ml methanol and spectrophotometrically analysed 
for percentage drug content. 
Percentage moisture content 
The transdermal patch was introduced to a desiccator at room 
temperature containing activated silica for one day. The patches 
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were repeatedly weighed the next day for constant weight was 
attained [54]. 
Folding endurance 
A longitudinal strip of a transdermal patch was cut and folded 
repeatedly and calculated the number of times the patch was folded 
at the same place without breaking/rupturing [55]. 
Transmission electron microscopy (TEM) 
The optimized midazolam niosomal transdermal patch NT5 was 
viewed under TEM where the electron beams were used to emit 
radiation through the sample to form an image [56-58]. 
Histopathological studies 
Source of porcine ear skin and its preparation 
The ear of the freshly sacrificed pig was collected from a local 
slaughter house at morning and was cleaned with distilled water to 
be used for the study by noon, housed at 23-27 °C. The underlying 
fat deposits were initially excised off uniformly and the skin layers 
from the outer. The skin preparation retaining all the layers was 
allowed to equilibrate for one hour in receptor buffer to retain its 
properties as live tissue. Later on the skin was stored in containers 
partly filled with formalin solution. 
Preparation of formalin solution  
Firstly 100 ml of formalin was solubilised in distilled water and to it 
disodium hydrogen phosphate and sodium hydrogen phosphate was 
added and pH was made up to 6.6. 
Preparation of porcine ear skin for histological studies 
The prepared pig skin was mounted between the compartments of 
Franz diffusion cell for ex vivo permeation studies. The 
histopathological studies of the treated skin were done for finding 
observable changes in tissue characteristics. For the study the 
optimised niosomal formulation, N5 and niosomal transdermal 
patch, NT5 was treated on control ear tissue and after fixation was 
viewed under the light microscope under standard atmospheric 
conditions [59-61].  
Stability studies 
The optimised niosomal formulations of niosome and transdermal 
patch were subjected to various stability studies for 45 d within 
refrigerator (4±2 °C) and room temperature (29±2 °C) in triplicate 
[62]. 
RESULTS AND DISCUSSION 
Preformulation studies 
Fourier transform infrared (FTIR) spectroscopy  
The FTIR of an obtained pure drug of midazolam and midazolam 
loaded niosomal transdermal patch was found to be in accordance 
with monograph (IP) as shown in fig. 1(A) and fig. 2(B) [63]. 
Solubility studies 
The pure drug is partially insoluble in distilled water and n-butyl 
alcohol and completely soluble in methanol, acetone, ethanol, 
isopropyl alcohol, PBS pH5.5. 
Melting point of the drug 
The melting point of the drug was found to be 158-160 °C and it was 
in accordance with that of the reference. 
Partition coefficient  
The partition coefficient of drug midazolam was found to be 4.5 and 
shows an amphiphilic character when entering body pH.  
Formulation of midazolam loaded niosomal transdermal patch 
The niosome of midazolam was formulated using thin film hydration 
method. The surfactants, Span 60 and soya bean oil (natural 
surfactant) with co-surfactant, cholesterol was used for formulating 
niosome using rotary vacuum evaporator. 2%w/v of span 60, 1% w/v 
of cholesterol and 0.75% w/v soya bean oil had the ability to convert 
within itself to a thin film in methanol chloroform solvent system. 
2%w/v of span 60 acts as a surfactant and stabilises the chemical 
attachments between the bilayer of niosome with cholesterol. The 1% 
w/v of cholesterol acts as co-surfactant and stabilises the 
biomembrane along with span 60 [64]. The 0.75% w/v soya bean acts 
as a natural surfactant and emulsifies or stabilises the niosomal 
membranes [65-66]. Methanol and chloroform were used as solvents 
to reconstitute the contents of the thin film obtained from the round 
bottom flask of rotary vacuum evaporator.  
The transdermal patch was prepared using solvent casting method 
using gelatin as natural polymer [67]. Gelatin 2%w/v was used to 
get the optimised transdermal patch formulation were gelatin is 
used for its excellent natural film-forming properties [68-69]. The 
prepared niosomes were loaded into the patch formulation to which 
turpentine oil was added as a natural permeation enhancer [70]. The 
formulations of niosomal transdermal patches are shown in table 
1(A) and table 1(B). 
 







Span 60 (mg) Cholesterol 
(mg) 




1) N1 10 1 0.5 0.75 5 3 
2) N2 10 1 1 0.25 3 2 
3) N3 10 1 1.25 0.5 6 4 
4) N4 10 1.75 1.25 1 8 6 
5) N5 10 2 1 0.75 10 8 
6) N6 10 2.5 1.5 1 9 5 
7) N7 10 3 1 0.75 8 6 
 















1) NT1 1 6 qs.20 5 4 
2) NT2 1 8 qs.20 2 2 
3) NT3 1 5 qs.20 0.1 1 
4) NT4 1 4 qs.20 3 0.05 
5) NT5 1 2 qs.20 1 0.1 
6) NT6 1 1 qs.20 2 0.25 
7) NT7 1 3 qs.20 4 5 
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Lamda max of midazolam in methanol and phosphate buffer 
solution (PBS) 
The absorption maxima of midazolam in both 10 ml of methanoland 
PBS pH5.5 was found to be 220 nm using UV-Vis spectrophotometer. 
Drug compatibility with excipients 
The FTIR spectrum of all individual excipients was compared with 
the FTIR spectrum of the two formulations. The drug, as well as 
excipients, exhibited no changes in its characteristic peaks when 
loaded to niosomal and transdermal patch formulation.  
X-ray diffraction studies 
The XRD pattern of drug midazolam, N5 niosomal formulation, and 
NT5 niosomal transdermal patch formulation are shown in fig. 
1(C) to fig. 1(E). The characteristic intense and sharp peaks in the 
XRD pattern of pure midazolam depicts the crystalline nature, 
appearing at 9.5, 11.7, 13.3, 20.7, 22.7 2-Theta values. During the 
formulation of niosomes, the number of intense peaks lowered and 
confined to 5.3 and 21.6 2-Theta values. The XRD pattern of 
niosomal transdermal patch formulation showed only one intense 
peak at 5.1 2-Theta values. While comparing the results of drug 
with optimized formulations, the concluding pattern shows a 
lower intensity and no. of peaks. This apparently illustrates that 
the extent of crystalline nature of midazolam was reduced when 
the drug was formulated as niosome and further loaded to a 
transdermal patch formulation. 
Characterisation 
Characterisation of niosomes 
Vesicle size 
The particle size distribution of midazolam niosomes assessed using 
DLS showed an average particle size of 116.1±84.46 d. nm. The size 
was analysed to be sufficiently small to penetrate the pores of 
stratum corneum as showed in fig. 2(A). 
 
 
Fig. 1: (A) FTIR Spectrum of midazolam loaded niosome, (B) FTIR Spectrum of midazolam loaded niosomal transdermal patch, (C) X-ray 
diffraction studies of pure drug, (D) X-ray diffraction studies of optimised N5 formulation,(E) X-ray diffraction studies of optimised NT5 
formulation 
Nair et al. 




In order to analyse the approach of all niosomal midazolam 
formulations and their ionic interaction with the biological 
membrane, the zeta potential was analysed to be 8.56±1.2mV. 
The zeta potential directly indicates the surface charge of the lipid 
nanocarrier. Due to its positive value, the lipid carrier interacts with 
the negatively charged biological membrane so as to increase the 
cellular uptake [71]. Thus the zeta potential of a stable dispersion of 
niosomes is shown in fig. 2(B). 
Entrapment efficiency 
The entrapment efficiency of all niosomes ranged between 
88.79±0.21% to 90.15±0.34% as shown in fig. 2(C). The maximum 
entrapment was found to be 90.15±0.34 % for the niosome 
formulation N5. The entrapment efficiency of niosomes was 
dependent on the concentrations of polymers used [72]. By 
increasing the concentration of polymers, multiple coating layers 
will be formed around the nanoparticle which will retard drug 
release [73]. 
SEM 
The SEM studies were done to examine the morphological shape of the 
niosomal midazolam. The SEM images for the midazolam niosome and 
niosome loaded transdermal patches are shown in fig. 2(D) and fig. 2(E) 
which confirms the smooth spherical nature of niosomes. 
TEM 
The optimised niosomal transdermal patch NT5 was examined to 
TEM studies were the niosomal particles were found to be nearly 
spherical. The size of the particles increased according to the 
molecular weight of gelatin [74]. The image depicted clear intact 
particles with the least aggregate formation even after loading 
niosome into the transdermal patch as seen in fig. 2(F). 
  
 
Fig. 2: (A)Vesicle size of niosomal midazolam(B) Zeta potential of niosomal midazolam(C) Entrapment efficiency of niosomal midazolam 
(D) SEM image of niosomal midazolam(E) SEM image of niosomal midazolam(F) TEM image of niosomal midazolam transdermal patch 
 
In vitro release studies 
The in vitro release studies of various formulations of midazolam 
loaded niosome was done for 8 h in acetate buffer pH5.5. A constant 
temperature and pressure conditions were maintained throughout 
the experiment. The drug release was found to be maximum by N5 
formulation with the highest release of 97.3±0.35%. The excipients 
used in the preparation of niosomes in a proportional concentration 
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played a major role in the release characteristics [75-76]. The in 
vitro drug release studies of midazolam niosomal formulations at 
different time intervals were shown in fig. 3. 
Kinetic model of in vitro drug release studies 
The drug release profile of N5 niosomal midazolam with highest 
drug release pattern was attributed to different kinetic models like 
Zero order model, First order Model, Higuchi’s diffusion model, and 
Koresmeyer peppas plot to interpret drug release by kinetic 
modelling [77]. The release kinetics of drug was found to be Zero 
order as the R2regression coefficient of the model was found to be 
0.9597. This was best fitted with Koresmeyer peppas plot (n = 
0.4201) which is greater than 0.5 depicting non fickian 
transportation mechanism as depicted in table 2 [78]. 
 
 
Fig. 3: In vitro release studies of different midazolam niosomal formulations 
(values are expressed as mean±standard deviation, n=3) 
 
Table 2: Kinetic models of optimised N5 niosomal formulation 
Zero-order release plot First order release plot Higuchi plot Koresmeyer peppas plot 
R2 R2 R2  n R2 
0.9597 0.9272 0.917  0.4201 0.9768 
 
Characterisation of niosomal transdermal patch 
Flatness 
The different formulations of midazolam loaded niosomal transdermal 
patch was measured in triplicate and there were slight variations in 
flatness between the different formulations indicating no significant 
stretching or constriction of the patches. The NT5 formulation showed 
highest uniformity in flatness as shown in fig. 4(A). 
Swelling ratio 
The swelling studies of all formulations were found to be a function 
of polymer concentration. The % swelling ranged from 22.96±0.03 
to 38.95±0.03as seen in fig. 4(B). It was seen that the polymer 
concentration varied with the amount of water it could absorb 
during the study and was found ideal for N5 formulation [79]. The 
swelling of the polymer was due to the dissolution of gelatin in the 
buffer as a function of temperature and time.  
Weight uniformity 
The average weight of different transdermal patch formulations 
ranged from 152.35±0.02 to 168.46±0.01 mg as seen in fig. 4(C). All 
the formulations were found to be having satisfactory results and 
has low standard deviation values within a formulation.  
Thickness 
The thickness of various transdermal patches prepared varied 
between 0.262±0.012 to 0.315±0.023 mm as shown in fig. 3(D). The 
difference in thickness showed very less standard deviation hence 
the formulations did not show any susceptible changes [80]. 
Percentage of drug content 
The drug content of different transdermal patches was found to be 
90.26±0.071 to 90.52±0.073 as shown in fig. 4(E). The values show 
least deviations depicting the uniform distribution of drug content 
throughout the patch. The drug retained within the patch was 
comparatively high for N5 formulation.  
Percentage moisture content 
The prepared patches showed minimum percentage moisture 
content ranging between 0.0021±0.002 % to 0.0038±0.004 % as 
shown in fig. 4(F). The lower concentration of moisture uptake helps 
in maintaining the preparation free from microorganism’s 
contamination [81]. The results ensures the maintenance of proper 
architecture and stability of patches which was found to be least 
within N5 formulations. 
Folding endurance 
The folding endurance of the patches was reported to be 234±6.36 
to 271±3.54 as shown in fig. 4(G). The patches N1 and N5 
formulations having an intermediate concentration of gelatin was 
found to be having the satisfactory results. This ability to retain the 
structural integrity helps the patch to be retained over the skin 
surface for a longer time without breaking [82, 83]. 
In vitro release studies 
The in vitro release studies of various formulations of midazolam 
loaded niosomal transdermal patch was also done for 8 h in phosphate 
buffer pH5.5. A constant temperature and pressure conditions were 
maintained throughout the experiment. The drug release was found to 
be maximum by NT5 formulation with the highest release of 
98.9±0.20%thus regarded as the optimised formulation. The release 
was initially found to be burst followed by the gradual sustained 
increase in free drug concentration. The hydrophilic polymer gelatin 
absorbs fluid and enables the significant swelling of the patch [84]. 
Thus along with plasticizers like PEG 4000, it enhances the drug 
release with improved and flexible characteristics [85-86]. The in vitro 
drug release studies of midazolam niosomal transdermal patch at 
different time intervals are shown in fig. 5. 
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Fig. 4: (A) Flatness, (B) Swelling ratio, (C) Weight uniformity, (D) Thickness, (E) Percentage drug content, (F) Percentage moisture 
content, (G) Folding endurance of different niosomal transdermal patch 
 
Kinetic model of in vitro drug release studies 
The drug release profile of midazolam loaded niosomal transdermal 
patch (NT5) with highest drug release pattern was attributed to 
different kinetic models like Zero order model, First order Model, 
Higuchi’s diffusion model, and Koresmeyar peppas plot to interpret 
drug release by kinetic modelling. The release kinetics of drug was 
found to be Zero order as the R2regression coefficient of the model 
was found to be 0.9565. This was best fitted with Koresmeyer 
peppas plot (n = 0.4953) which is greater than 0.45 depicting non 
fickian transportation mechanism. The kinetics also obeys the 
Higuchi plot were R2 value is almost 0.9585 as illustrated in table 3. 
 
 
Fig. 5: In vitro release studies of different midazolamloaded niosomaltransdermal patch formulations, (values are expressed as 
mean±standard deviation, n=3) 
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Table 3: Kinetic models of optimised NT5 niosomal transdermal patch formulation 
Zero order release plot First order release plot Higuchi plot Koresmeyer peppas plot 
R2 R2 R2  n R2 
0.9565 0.9019 0.9585  0.4953 0.9639 
 
Ex-vivo permeation studies and steady state flux value 
determination 
The permeation studies were done in Franz diffusion cell with 
normal pig skin mucosa for 8 h. The mucosa biologically resembles 
human skin mucosa and thus ex vivo studies were done with pig skin 
[87]. The pigskin mucosa was experimented with the optimized 
niosomal formulation N5, optimised niosomal transdermal patch 
NT5 and buffer containing drug preparation (Control). The samples 
withdrawn at each intervals were analysed and the cumulative 
amount of drug permeated v/s time was plotted. The permeation 
was found to be enhanced in case of niosomal midazolamN5 and 
when the niosome was loaded to transdermal patch NT5 in a 
controlled manner from the porcine skin. The permeation is 
sustainably enhanced for formulations with an optimum 
concentration of Span 60 due to its increased wettability, drug 
distribution and ability to lower the surface tension [88]. The 
natural oil, soya lecithin provides an improved penetration effect by 
increasing its permeability into the carrier vesicles and thereby 
decreasing the resistance of molecules by enhancing the fluidity [89-
90]. The flux values of optimised formulations reported the drug 
penetrated during each hour per square centimeter and established 
a relation between an amount of drug released and swelling of patch 
[91]. The ex vivo permeation studies of the above mentioned 3 
formulations is given in fig. 6. The values of permeation parameters 
(steady state flux {J}, permeation coefficient {P} and enhancement 
ratio of optimized midazolam loaded niosomal transdermal patch 
(NT5), optimised midazolam loaded niosome (N5), midazolam API 
loaded transdermal patch and drug in PBS pH 5.5 (control drug 
solution) was illustrated in table 4. 
 
 
Fig. 6: Ex vivo permeation studies of optimised midazolam loaded niosome and midazolamloaded niosomal transdermal patch in 
comparison to control drug solution (values are expressed as mean±standard deviation, n=3) 
 
Table 4: Flux, enhancement, and permeation coefficient of optimized niosomal midazolam transdermal patch NT5 
S. 
No. 




noisome (N5) (*from 
previous study) 
Midazolam API loaded 
transdermal patch 
Drug in PBS pH5.5 
(control drug 
solution) 
1. Steady state flux–J (µg/cm2/h) 4.26±0.31 1.13±0.22 0.62±0.24 0.56±0.14 
2. Enhancement ratio (basis of 
control drug solution) 
7.61 2.01 1.11 - 
3. Enhancement ratio (basis of 
midazolam API loaded 
transdermal patch) 
6.84 1.81 - - 
4. Permeation coefficient–
Kp(cm2/h) 
0.0062±0.47 0.0031±0.33 0.007±0.28 0.56±0.42 
(Values are expressed as mean±standard deviation, n=3) 
 
The flux value obtained for optimised midazolam loaded niosomal 
transdermal patch (NT5) was found to be 4.26 µg/cm2/h and 
permeation coefficient of 0.0062 cm2/h. These values correlate that 
optimised midazolam loaded niosomal transdermal patch (NT5) 
showed greater steady state flux values when compared to 
midazolam loaded niosome (N5), midazolam API loaded 
transdermal patch and control drug solution. The ex vivo permeation 
parameters confirms that the permeation of midazolam loaded 
niosomes across the porcine skin barrier is significantly higher when 
compared to the drug in PBS pH 5.5 (control drug solution). The 
primary reason for niosomes to enhance the permeation of drugs is 
through the structural modification in stratum corneum layers. Due 
to the effect of natural permeation enhancers and non-ionic 
surfactants used in the formulation of niosomes, the intercellular 
lipid barrier gets dramatically loosened. The enhanced permeability 
may also occur due to aggregation and fusion of midazolam loaded 
niosome at the interface of stratum corneum and generation of high 
thermodynamic activity of midazolam which was highly 
concentrated in the bilayers. As a result, enhanced flux is achieved 
due to the direct transfer of drug from vesicles to the skin. The fig. 7 
shows the comparison of steady state flux of selected formulations 
through porcine skin layers after ex vivo permeation studies. 
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Fig. 7: Comparison of steady-state flux of selected formulations through porcine skin layers (Values are expressed as mean±standard 
deviation, n=3) 
 
Statistical analysis by student t-test 
The statistical analysis by student t-test was performed for the 
steady state flux values of different formulations. The statistical 
analysis by student t-test revealed that there is significant difference 
in the steady state flux value of the optimised midazolam loaded 
niosomal transdermal patch (NT5) and optimised midazolam loaded 
niosome (N5) with that of drug in PBS pH 5.5 (control drug 
solution), where (P<0.05) thus very significant. Hence the difference 
is statistically significant.  
  
 
Fig. 8: Histopathological evaluation of porcine skin. 8(A) Porcine skin treated with midazolamloaded niosome N5, 8(B) Porcine skin treated with 
midazolamloaded niosomal transdermal patch, 8(C) porcine skin treated with control (Drug in buffer solution), 8(D) Normal porcine skin 
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Fig. 9: (A) Particle size of optimised midazolam loaded niosome (N5) during stability studies at different conditions, (values are 
expressed as mean±standard deviation, n=3) 
 
 
Fig. 9: (B) Entrapment efficiency of optimised midazolam loaded niosomal transdermal patch (NT5) during stability studies at different 
conditions (values are expressed as mean±standard deviation, n=3) 
 
Histopathological examination 
The porcine mucosa subjected to ex vivo permeation studies were 
assessed for histopathological changes [92]. The fig. 8(A),(B),(C) 
shows that neither the optimized midazolam loaded niosome (N5), 
optimised midazolam loaded niosomal transdermal patch (NT5) and 
drug loaded in buffer solution PBS pH 5.5, shows no significant 
changes in the histological pattern when compared to normal 
mucosadepicted in fig. 8 (D). Hence the midazolam loaded niosomal 
transdermal patch does not cause any irritation and is safe for 
transdermal application [93]. 
Stability studies 
The stability studies of optimised midazolam loaded niosome (N5) 
and midazolam loaded niosomal transdermal patch (NT5) was done 
in the refrigerator (4±2 °C) and room temperature (30±2 
°C)/65±5%RH for 90 d[94]. The optimised midazolam loaded 
niosome was subjected to particle size analysis which reviewed that 
there are no major variations in its stability in both room and 
refrigerator temperatures as illustrated in fig. 9 (A) [95]. 
The entrapment efficiency of optimised midazolam loaded niosomal 
transdermal patch (NT5) was measured during different study 
intervals and illustrated in fig. 9 (B), confirmed that the formulations 
were stable at both the temperature conditions. 
CONCLUSION 
Epilepsy is characterized by the persistent increase of neuronal 
perturbation and inhibitory synaptic current breakdown which was 
treated by conventional antiepileptic drugs with high dosage and 
frequency of administration. The main purpose of this study was to 
develop a sustained delivery of midazolam loaded niosome through 
transdermal route for a patient who has frequent daily dosages 
where formulation effectively improved its release rate and 
permeation characteristics. Among the formulations prepared, 
midazolam loaded niosome (N5) and midazolam loaded niosomal 
transdermal patch (NT5) was fixed to be optimised formulations, 
which had maximum drug release of 97.3±0.35% and 98.9±0.20% 
and greater permeation than control drug solution. The flux and 
permeability coefficient was found to be higher for midazolam loaded 
niosomal transdermal patches when compared to control drug 
formulation which was statistically significant (P<0.05). The 
histopathological studies showed no significant alteration in its normal 
physiology when optimised formulations was permeated through 
porcine skin. The optimised formulations of niosome and transdermal 
patches were found be having good stability at room and refrigerator 
conditions. Thus formulated midazolam loaded niosomal transdermal 
patch represents to be an efficient and stable vesicular carrier for the 
transdermal delivery of an antiepileptic drug like midazolam which 
could be further studied by using in vivo animal models. 
Nair et al. 




All the author have contributed equally 
CONFLICT OF INTERESTS  
Declared none 
REFERENCES 
1. Suruchi S, Vaishali D. Epilepsy–a comprehensive review. Int J 
Pharm Res Rev 2013;2:61-80. 
2. Jessica JFW, Ingrid ES, Robert SF. The new definition and 
classification of seizures and epilepsy. Epilepsy Res 2018;139:73-9. 
3. Karthika R, Krishnapriya M, Anupriya, Nair SC. An outlook to 
non-pharmacological and novel approaches to combat the 
uncurable firing disorder. Int J Pharm Sci Rev Res 2016;40:55-61.  
4. Bateman LM, Begley CE, Ben Menachem E. Overcoming barriers to 
successful epilepsy management. Epilepsy Curr 2012;12:158-60.  
5. Yevgeny B, Yero S, Kyung-Il P, Bonnie R, Wendy P, Kimberly L, 
et al. Staged anticonvulsant screening for chronic epilepsy. Ann 
Clin Translation Neurol 2016;3:908–23. 
6. Jacqueline AF, White HS, Henrik K, Gregory LH, Michael DP, 
Andrew JC, et al. Development of new treatment approaches for 
epilepsy: Unmet needs and opportunities. Epilepsia 2013;54:3-12.  
7. Mark M. Recent advances in epilepsy. J Neurol 2017;264:1811-24. 
8. Cui TL, Ying ZZ, Ho LW, Jun C, Lei P, Xin QT. Current approaches 
to enhance CNS delivery of drugs across the brain barriers. Int J 
Nanomed 2014;10:2241-57. 
9. Shefrin S, Sreelaxmi CS, Vishnu V, Nair SC. Enzymosomes: a 
rising effectual tool for targeted drug delivery system. Int J 
Appl Pharm 2017;9:1-9.  
10. Chen DK, Fisher RS. New route for delivery of anti-epileptic 
medications. Acta Neurol Taiwanica 2006;15:225-31. 
11. Revathy BM, Lakshmi VS, Aiswarya MU, Keerthana R, Nair SC. 
Porphysomes-a paradigm shift in targeted drug delivery. Int J 
Appl Pharm 2018;10:1-6. 
12. Pravina H, Nivedita N, Sujay C. Niosome: a promising 
pharmaceutical drug delivery. Int J Pharm Drug Anal 
2014;2:425-31. 
13. Shirsand SB, Para MS, Nagendrakumar D, Kanani KM, Keerthy 
D. Formulation and evaluation of Ketoconazole niosomal gel 
drug delivery system. Int J Pharm Investig 2012;2:201-7. 
14. Thagele R, Mishra, Pathak AK. Formulation and 
characterization of clarithromycin-based nanoparticulate drug 
delivery system. Int J Res Pharm Life Sci 2011;2:510–5. 
15. Saeid M, Afra. Nano-niosomes as nanoscale drug delivery systems: 
an illustrated review. J Controlled Release 2014;185:22-36.  
16. Gyanendra S, Harinath D, Shailendra KS, Shubhini AS. Niosomal 
delivery of isoniazid–development, and characterization. Trop J 
Pharm Res 2011;10:203-10. 
17. Ahmad U, Gihan F, Tahani EF. Performance of meloxicam 
niosomal gel formulations for transdermal drug delivery. Br J 
Pharm Res 2016;12:1-14. 
18. Parika S, Nitya S, Basant S, Neha K. Development and in vitro 
evaluation of ambroxol hydrochloride niosome using thin film 
hydration method. IOSR J Pharm Biol Sci 2016;11:10-8.  
19. Ramona K, Haema T. Lipid peroxidation: its effects on the 
formulation and pharmaceutical emulsions. Asian J Pharm Sci 
2017;12:401-11. 
20. Nasseri B. Effect of cholesterol and temperature on the elastic 
properties of niosomal membranes. Int J Pharm 2005;300:95-
101. 
21. Ravi G, Gupta NV. The treatment of Alzheimer's disease by 
using Donepezil loaded the transdermal patch. J Chem Pharm 
Res 2015;7:806-13. 
22. Lakshmi PK, Mounika K, Saroja CH. Transdermal permeation 
enhancement of lamotrigine using terpenes. J Pharm Care 
Health Sys 2014;1:1-6. 
23. Thakur V, Arora S, Prashar B, Vishal P. Niosomes and 
liposomes-vesicular approach towards transdermal drug 
delivery. Int J Pharm Chem Sci 2012;1:981-93. 
24. Ahlam ZA, Maeliosa TCMc, Ryan FD. Transdermal drug 
delivery: innovative pharmaceutical developments based on 
disruption of barrier properties of stratum corneum. 
Pharmaceutics 2015;4:438-70. 
25. Hams AS, Lustig W, Yang L, Bozcar A, Buckheit KW, Buckheit 
RW. In vitro and ex vivo evaluations on transdermal delivery of 
HIV inhibitor IQP-0410. PLoS One 2013;8:63-70. 
26. Krishnapriya M, Karthika R, Nair SC. Antiepileptic rectal 
hydrogel loaded with carbamazepine–rice bran wax 
microspheres. Asian J Pharm Clin Res 2017;10:264-70. 
27. Gorle AP. A way to increase the effectiveness of paracetamol 
drug through transdermal patch. Int Res J Pharm 2016;7:30-4. 
28. Florian L, Nesrine H, Pascal L, Emmanuel C, Ghassen B, Fillatre 
P, et al. Propofol, midazolam, vancomycin and cyclosporine 
therapeutic drug monitoring in extracorporeal membrane 
oxygenation circuits primed with whole human blood. Crit Care 
2015;19:772-5. 
29. Jithendra KP, Sudhir M, Prasad AR, Saradhi AP, Reddy ES. 
Dissolution profile enhancement of poorly water-soluble drug 
midazolam by using solid dispersion technique. Panacea J 
Pharm Pharm Sci 2013;1:5-10.  
30. Ziyaur R, Ahmed SZ, Raghu S, Vilayat AS, Mansoor AK. 
Improvement of physicochemical propertries of an 
antiepileptic drug by salt engineering. AAPS Pharm Sci Tech 
2012;13:793-801. 
31. Jayashree BT, Priyanka PS, Rashmi VT, Kamlesh JW, Milind JU. 
Formulation and pharmacodynamic investigations of 
lamotrigine microspheres in pentylenetetrazole induced 
seizures in rats. Asian J Pharm 2017;11:215-24. 
32. Lopalco A, Ali H, Denora N, Rytting E. Oxcarabmazepine loaded 
polymeric nanoparticles: development and permeability studies 
across in vitro models of the blood-brain barrier and human 
placental trophoblast. Int J Nanomed 2015;10:1895-996. 
33. Kumar PA, Singh R, Karthick K, Arulkumaran KSG. Formulation 
and evaluation of sustained released niosomes containing 
pregabalin. Int J Res Pharm Life Sci 2013;4:2770-4. 
34. Asthana GS, Asthana A, Singh D, Sharma PK. Etodolac 
containing topical niosomal gel: formulation development and 
evaluation. J Drug Delivery 2016;10:32-40. 
35. Stan CD, Tataringa G, Gafitanu C, Dragan M, Braha S, Popescu 
MC, et al. Preparation and characterization of niosomes 
containing metronidazole. Farmacia 2013;61:1178-85. 
36. Cherukuri S, Batchu UR, Mandava K, Cherukuri V, Ganapuram 
KR. Formulation and evaluation of transdermal drug delivery of 
Topiramate. Int J Pharma Investig 2017;7:10-7. 
37. Shivhare UD, Wasnik SV. Formulation development and 
evaluation of niosomal gel for transdermal delivery of an 
antihypertensive drug. Int J Biopharm 2013;4:231-8. 
38. Ali AMA, Sarhan HA, Magdy T. Preparation and characterization 
of phenytoin sodium niosomes for enhanced closure of skin 
injuries. Int J Pharm Pharm Sci 2014;6:542-6. 
39. Satyavathi V, Hasanthali AA, Ilavarasan R, Sangeetha T. 
Formulation and evaluation of niosomal in situ gel ocular 
delivery systrm of Brimonidine tartrate. Int J Life Sci Pharm Res 
2012;2:82-95. 
40. Pardakhty A, Varshosaz J, Rouholamini A. In vitro study of 
polyoxyethylene alkyl ether niosomes for delivery of insulin. 
Int J Pharm 2007;328:130-41.  
41. Samifar S, Akki R, Ramya MG, Naik VV. Development and 
characterisation of carbamazepine loaded non-ionic surfactant 
vesicles. Acta Chim Pharm Indica 2015;5:29-40. 
42. Lopez T, Cuevas JL, Jardon G, Gomez E, Ramirez P, Novaro O, et 
al. Preparation and characterization of antiepileptic drug 
encapsulated in sol-gel titania nanoparticles as controlled 
release system. Med Chem 2015;10:161-72. 
43. Akhtar N, Arkvanshi S, Bhattacharya SS, Verma A, Pathak K. 
Preparation and evaluation of buflomedil hydrochloride niosomal 
patch for transdermal delivery. J Liposome Res 2014;10:1-11. 
44. Begum SS, Prakash PR, Jaharabee B, Reddy YD, Ravishankar V, 
Bhaskar NV. Preparation and evaluation of niosomes using 
clopidogrel bisulphate as a model. Inventi Impact NDDS 
2015;4:170-7. 
45. Singh G, Dwivedi H, Saraf SK, Saraf SA. Niosomal delivery of 
isoniazid-development and characterization. Trop J Pharm Res 
2011;10:203-10. 
46. Rajendran V. Effect of niosomes in the transdermal delivery of 
antidepressant sertraline hydrochloride. J Sci Innov Res 
2016;5:138-43. 
Nair et al. 
Int J App Pharm, Vol 11, Issue 2, 2019, 31-43 
 
42 
47. Rahman L, Arisanty, Manggau. Niosomal transdermal gel 
formulation of curcumin having an anti-inflammatory effect in 
experimental rat models. J Chem Pharm Res 2015;7:843-9. 
48. Singh A, Bali A. Formulation and characterization of 
transdermal patches for controlled delivery of duloxetine 
hydrochloride. J Anal Sci Technol 2016;7:1-13. 
49. Paul A, Fathima M, Nair Sc. Intra nasal in situ gelling system of 
lamotrigine using ion activated mucoadhesive polymer. Open 
Med Chem J 2017;11:222-44. 
50. Kumar KPS, Bhowmik D, Singh RK. Formulation and evaluation of 
ramipril transdermal patch. Indo Am J Pharm Res 2014;4:1850-6. 
51. Nanda S, Saroha K, Yadav B, Sharma B. Formulation and 
characterization of the transdermal patch of amlodipine 
besylate. Int J Pharm Chem Sci 2012;1:953-69. 
52. Kavitha K, Kumar DP. Development of transdermal patches of 
nicardipine hydrochloride: an attempt to improve 
bioavailability. Int J Res Pharm Biomed Sci 2010;1:113-21. 
53. Bharkatiya M, Nema RK, Bhatnagar M. Development and 
characterization of transdermal patches of metoprolol tartrate. 
Asian J Pharm Clin Res 2010;3:130-4. 
54. Kurakula M, Ahmed OAA, Fahmy UA, Ahmed TA. Solid lipid 
nanoparticles for transdermal delivery of avanafil: 
optimisation, formulation, in vitro and ex vivo studies. J 
Liposome Res 2016;26:288-96. 
55. Salih OS, Samein LH, Ali WK. Formulation and in vitro 
evaluation of rosuvastatin calcium niosomes. Int J Pharm 
Pharm Sci 2013;5:525-35. 
56. Mohawed OAM, Ashmoony MM, Elgazayerly ON. Niosome 
encapsulated clomipramine for transdermal controlled 
delivery. Int J Pharm Pharm Sci 2014;6:567-75. 
57. Patel KK, Kumar P, Thakkar HP. Formulation of niosomal gel 
for enhanced transdermal lopinavir delivery and its 
comparative evaluation with ethosomal gel. AAPS 
PharmSciTech 2012;13:1502-10. 
58. Gupta A, Singh S, Kotla NG, Webster TJ. Formulation and 
evaluation of a topical niosomal gel containing a combination of 
benzoyl peroxide and tretinoin for antiacne activity. Int J 
Nanomed 2015;10:171-82. 
59. Thakur R, Anwer MK, Shams MS, Ali A, Khar RK, Shakeel F. 
Proniosomal transdermal therapeutic system of Losartan 
potassium: Development and Pharmacokinetic evaluation. J 
Drug Target 2009;17:442-9. 
60. Chaudhari SP, Chatur VM. Development of valproic acid in situ gel 
formulation for epilepsy. Indian J Pharm Educ Res 2013;47:31-41.  
61. Rajan M, Raj V. Formation and characterization of chitosan-
polylactic acid-polyethylene glycol-gelatin nanoparticles: a 
novel biosystem for controlled drug delivery. Carbohydr Polym 
2013;98:951-98. 
62. Chaw CS, Kim KYA. Effect of formulation compositions on 
niosomal preparations. Pharm Dev Tech 2013;18:667-72. 
63. Cizinauskas V, Elie N, Brunelle A, Briedis V. Skin penetration 
enhancement by natural oils for dihydroquercetin delivery. 
Molecules 2017;22:1-16.  
64. Lakshmi PK, Mounika K, Saroja CH. Transdermal permeation 
enhancement of lamotrigine using terpenes. J Pharma Care 
Health Sys 2014;1:1-6. 
65. Sanjeev KP, Chandana H, Dinesh P, Pralay M. Biodegradable 
polymers for potential delivery systems for therapeutics. Adv 
Polym Sci 2013;254:169-202. 
66. Paul S, Jayan A, Sasikumar CS. Physical, chemical and biological 
studies of gelatin/chitosan-based transdermal films with 
embedded silver nanoparticles. Asian Pac J Trop Dis 
2015;5:975-86.  
67. Wang FL, Ji HM, Zhu JY, Guan YZ, Chen YJ. Penetration 
enhancement effect of turpentine oil on transdermal film of 
Ketorolac. Trop J Pharm Res 2015;14:1341-8. 
68. Honary S, Zahir F. Effect of zeta potential on the properties of 
nano-drug delivery systems–a review (Part 1). Trop J Pharm 
Res 2013;12:255-64. 
69. Nair SC, Anoop KR. Local antimicrobial delivery of 
satranidazole loaded cross-linked periodontal chips using bio 
degradable polymers. Int J Pharm Pharm Sci 2013;5:839-47. 
70. Sambhakar S, Paliwal S, Sharma S, Singh B. Formulation of 
risperidone loaded proniosomes for effective transdermal 
delivery: an in vitro and in vivo study. Bull Fac Pharm Cairo 
Univ 2017;55:239-47. 
71. Jacob S, Nair AB, Al-Dhubiab BE. Preparation and evaluation of 
niosomal gel containing acyclovir for enhanced dermal 
deposition. J Liposome Res 2017;27:283-92. 
72. Lu Z, Yeh TK, Tsai M, Au JL, Weintjes MG. Paclitaxel-loaded 
gelatin nanoparticles for intravesial bladder cancer therapy. 
Clin Cancer Res 2004;10:7677-84.  
73. Mokhtar M, Sammour OA, Hammad MA, Megrab NA. Effect of 
some formulation parameters on flubiprofen encapsulation and 
release rates of niosomes prepared from proniosomes. Int J 
Pharm 2008;361:104-11. 
74. Bansal S, Aggarwal G, Chandel P, Harikumar SL. Design and 
development of cefdinir niosomes for oral delivery. J Pharm 
Bioallied Sci 2013;5:318-25. 
75. Jain SK, Chourasia MK, Sabitha M, Jain R, Jain AK, Ashawat M, et 
al. Development and characterisation of transdermal drug 
delivery systems for diltiazem hydrochloride. J Drug Delivery 
2003;10:169-77. 
76. Aswathy SN, Vidhya KM, Saranya TR, Sreelakshmy KR, Nair SC. 
Mucoadhesive buccal patch of cefixime trihydrate using 
biodegradable natural polymer. Int J Pharm Pharm Sci 
2014;6:366-71. 
77. Jithendra B, Subhash P, Pathak AK. Development and optimisation 
of transdermal systems of lisinopril dehydrate: employing 
permeation enhancers. Iran J Pharm Sci 2010;6:245-51.  
78. Subramanian K, Indumathi S, Vijayakumar V. Fabrication and 
evaluation of chitosan-gelatin composite film as a drug carrier 
for in vitro transdermal delivery. Int J Pharm Sci Res 
2014;5:438-47.  
79. Mutalik S, Udupa N. Glibenclamide transdermal patches: 
physicochemical, pharmacodynamics and pharmacokinetic 
evaluations. J Pharm Sci 2004;93:1577–94. 
80. Ataurrahman F, Rasale, Ansari H. Formulation, development 
evaluation of flexible polymeric topical antifungal film (TAF). 
Int J Adv Pharm Med Bioallied Sci 2015;3:137-41. 
81. Yousuf M, Ahmad M. Ketotifan fumarate and Salbutamol 
sulphate combined transdermal patch formulations: in vitro 
release and ex vivo permeation studies. Indain J Pharm Sci 
2013;75:569-77. 
82. Foox M, Zilberman M. Drug delivery from gelatin-based 
systems. Expert Opin Drug Delivery 2015;12:1547-63. 
83. Abdelbary GA, Aburahma MH. Oro-dental mucoadhesive 
proniosomal gel formulation loaded with lornoxicam for 
management of dental pain. J Liposome Res 2013;25:107-21. 
84. Narayanan D, MGG HL, Koyakutty M, Nair S, Menon D. Poly-
(ethylene glycol) modified gelatin nanoparticles for sustained 
delivery of the anti-inflammatory drug Ibuprofen-Sodium: an in 
vitro and in vivo analysis. Nanomedicine 2013;9:818-28. 
85. Tanwar YS. Formulation and evaluation of transdermal films of 
salbutamol sulphate. Dhaka Univ J Pharm Sci 2005;4:93–7. 
86. Panchagnula R, Desu H, Jain A, Khandavilli S. Feasibility studies 
of dermal delivery of paclitaxel with binary combinations of 
ethanol and isopropyl myristate, role of solubility, partitioning 
and lipid bilayer perturbation. Farmaco 2005;60:894–9. 
87. Cocera M, Lopez O, Coderch L, Parra JL, de la Maza A. 
Permeability investigations of phospholipids liposomes by 
adding cholesterol. Colloids Surf A 2003;221:9-17. 
88. Bajpai AK, Choubey J. Design of gelatin nanoparticles as 
swelling controlled delivery system for chloroquine phosphate. 
J Mater Sci Mater Med 2006;17:345-58. 
89. Zhang K, Zhang Y, Li Z, Li N, Feng N. Essential oil-mediated 
glycerosomes increase transdermal paeoniflorin delivery: 
optimization, characterization, and evaluation in vitro and in 
vivo. Int J Nanomed 2017;12:3521-32. 
90. Castaneda PS, Chavez JJE, Aguado AT, Cruz IMR, Contreras 
LMM. Design and evaluation of transdermal patch with 
atorvastatin. Farmacia 2017;65:908-16. 
91. Abd E, Yousef SA, Pastore MN, Telaprolu K, Mohammed YH, 
Namjoshi S, et al. Skin models for the testing of transdermal 
drugs. Clin Pharmacol 2016;8:163-76. 
92. Sabitha M, NS Rejinold, Amrita N, Vinoth KL, Shantikumar VN, 
Rangasamy J. Curcumin loaded chitin nanogels for skin cancer 
treatment via the transdermal route. Nanoscale 2012;4:239-50. 
Nair et al. 
Int J App Pharm, Vol 11, Issue 2, 2019, 31-43 
 
43 
93. Ridy MSE, Yehia SA, Mohsen AM, Awdan SAE, Darwish AB. 
Preparation, characterisation and in vivo evaluation of 
Span60Lornoxicam niosomes. Res J Pharm Biol Chem Sci 
2017;8:398-411. 
94. Shinde UA, Kanojiya SS. Serratiopeptidase niosomal gel with 
potential in topical delivery. J Pharm 2014;10:295-382. 
95. Mohawed OA, Ashmoony MME, Elgazayerly ON. Niosome 
encapsulated clopirmine for transdermal controlled delivery. 
Int J Pharm Pharm Sci 2014;6:567-75. 
 
